CytomX Therapeutics, Inc. - Special Call Transcript
Good day, ladies and gentlemen, and welcome to CytomX Therapeutics conference call. (Operator Instructions) As a reminder, this call may be recorded.
I would now like to introduce your host for today's conference call, Mr. Christopher Keenan, Vice President of Investor Relations. Chris, you may begin.
Thank you, Jerome. Good afternoon, and thank you for joining us. Earlier today, we issued a press release announcing CytomX' achievement of a $40 million milestone as part of the company's AbbVie CD71 partnership and providing a clinical-stage pipeline update given the impact of the COVID-19 pandemic. This press release and a recording of this call can be found under the Investors and News section of our website at cytomx.com.
With me today are CytomX' President, Chief Executive Officer and Chairman, Dr. Sean McCarthy; CytomX' Chief Development Officer, Dr. Amy Peterson; and CytomX' newly appointed Chief Financial Officer, Carlos Campoy.
During
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
